Book profits in Ranbaxy Labs: Daljeet Kohli

Daljeet Kohli, Head of Research at IndiaNivesh Securities Private Limited advised booking profits in Ranbaxy Labs.

Kohli told CNBC-TV18, “The upside is very limited in Ranbaxy Labs and I would rather advice to book profits immediately because the consistent poor performance will takes its toll on the stock. We are looking at something like Rs 400-450 range very soon. On the upside Rs 475 is our target.” The stock fell 2.78 percent to close at Rs 443.80 amid large volumes on Bombay Stock Exchange.